Cornea Sense, a Finnish medtech company and Aalto University spinout, has successfully secured over €1.1 million in a pre-seed funding round. The financing was led by Innovestor Angel CoFund and prominent angel investors, supplemented by a Business Finland R&D grant. This capital injection will accelerate the development of the company's novel ophthalmic diagnostic technology for measuring corneal hydration.
Pioneering a New Diagnostic Frontier
The company is developing a unique system that combines terahertz sensing with optical coherence tomography (OCT) to provide non-invasive measurements of corneal hydration. This clinically significant parameter currently lacks a practical and direct method of assessment in standard ophthalmology. Cornea Sense's innovation aims to transform this unmeasured variable into a quantifiable and actionable piece of clinical data.
From University Research to Commercial Venture
The technology's journey began with research at Aalto University in 2018, which evolved into a two-year Business Finland commercialization project from 2024 to 2025. During this period, the team developed a functional prototype, established key clinical partnerships, and built the strategic foundation for a commercial enterprise. The company was officially founded in January 2026 to bring this promising research to the global market.
Strategic Use of Pre-Seed Capital
The newly acquired funds are earmarked for several critical development milestones, including the creation of a human-compatible research prototype. Cornea Sense will also conduct extensive technical and clinical validation activities and perform essential preclinical studies. These efforts are crucial for navigating regulatory pathways and gathering data to support future product commercialization.
Dr. Anton Chernenko, CEO of Cornea Sense, noted that while corneal hydration is not a common metric, its clinical value is quickly recognized by ophthalmologists. He explained that the primary barrier has been the absence of a practical measurement tool, a challenge his company is now poised to overcome. The goal is to empower clinicians with data that can significantly improve their decision-making processes.
Investor Confidence and Future Outlook
The investment round saw participation from Innovestor Angel CoFund and experienced investors like eye surgeon Matts Linder and Patrick Aisher of Kinled Holding. This backing from both venture capital and industry experts signals strong confidence in the company's technology and its potential market impact. The combination of private investment and public grants provides a robust financial base for the company's ambitious plans.
Looking ahead, Cornea Sense is focused on advancing its technology while building the necessary technical, clinical, and regulatory framework for market entry. The ultimate objective is to de-risk key development milestones and progress toward a globally scalable ophthalmic diagnostic product. This will involve generating robust data and expertise to validate the technology's efficacy and utility in clinical settings.
This successful pre-seed funding round marks a pivotal moment for Cornea Sense, providing the resources to transition its innovative technology from the laboratory to clinical application. By addressing a long-standing gap in ophthalmic diagnostics, the company is well-positioned to enhance eye care standards globally. The investment accelerates its mission to provide ophthalmologists with a vital new tool for improving patient outcomes.